Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

Employee Rating

4.0More
TypePublic
HQSan Diego, US
Founded2008
Size (employees)139 (est)
Websiteotonomy.com
Otonomy was founded in 2008 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Otonomy

Paul E. Cayer

Paul E. Cayer

Chief Financial and Business Officer

Otonomy Office Locations

Otonomy has an office in San Diego
San Diego, (HQ)
6275 Nancy Ridge Dr
Show all (1)
Report incorrect company information

Otonomy Financials and Metrics

Otonomy Revenue

Otonomy's revenue was reported to be $1.24 m in FY, 2017
USD

Revenue (Q3, 2018)

113.0k

Gross profit (Q3, 2018)

(49.0k)

Gross profit margin (Q3, 2018), %

(43.4%)

Net income (Q3, 2018)

(12.5m)

EBIT (Q3, 2018)

(13.0m)

Market capitalization (4-Dec-2018)

72.0m

Closing stock price (4-Dec-2018)

2.4

Cash (30-Sep-2018)

21.4m
Otonomy's current market capitalization is $72 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

683.0k1.2m

Cost of goods sold

1.7m3.1m

Gross profit

(981.0k)(1.9m)

Gross profit Margin, %

(144%)(151%)
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

139.8m158.7m24.2m18.5m

Accounts Receivable

91.0k107.0kwdxefcqufszuzezftuxetqsqxt

Inventories

1.6b5.3m1.4m6.0k

Current Assets

157.7m188.2m202.2m122.4m
Quarterly
USDQ3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

165.2m190.3m176.6m244.3m46.6m19.8m13.7m22.3m16.9m23.2m19.0m21.4m

Accounts Receivable

146.0k2.0k87.0k178.0k76.0k126.0k133.0k14.0k45.0k

Inventories

614.0k913.0k1.7m1.2m1.2m1.2m

Current Assets

167.3m216.1m204.4m270.7m245.6m222.7m173.6m155.3m139.5m112.7m102.4m95.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(42.9m)(61.7m)(110.6m)(90.1m)

Depreciation and Amortization

213.0k358.0k708.0k1.3m

Inventories

(1.4m)153.0k

Accounts Payable

(309.0k)1.7m(2.2m)(398.0k)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(29.7m)(27.6m)(27.1m)

Inventories

614.0k913.0k1.7m1.2m1.2m

Accounts Payable

1.7m1.9m4.0k2.1m2.4m800.0k934.0k212.0k1.3m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Otonomy Operating Metrics

FY, 2016

Patents Pending

115

Phase II Trials Products

2

Phase III Trials Products

2

Preclinical Phase Products

1
Show all operating metrics
Report incorrect company information

Otonomy Online and Social Media Presence

Embed Graph
Report incorrect company information

Otonomy News and Updates

Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. EDT Conference call and webcast today at 4:30 p.m. EDT

Ultimate Analysis on Meniere ’s disease Market & Global Forecast to 2023

Meniere’s disease market Analysis, by diagnosis (hearing assessment, balance assessment, and others), by treatment (medication, surgery, and others), by end user & is to Grow with USD 6380.3 Million, 8.5% of CAGR Posted via Industry Today. Follow us on Twitter @IndustryToday

Magnificent Expansion of Meniere ’s disease Market: Valuation USD 6380.3 Million, 8.5% of CAGR By 2023

Market Research Future published a research report on “Meniere’s Disease Market Research Report- Global Forecast till 2023“– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Otonomy Blogs

Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference

SAN DIEGO , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David A. Weber , Ph.D., president and chief executive officer, will participate in a fireside chat at

Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss

Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today is presenting data on the

Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the

Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"

SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple presentations related to the company's programs in hearing loss and tinnitus at the upcoming Society

Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update

Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results

Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting

Positive Results from AVERTS-2 Phase 3 Clinical Trial will Support Submission for U.S. Registration and Provide Basis for Ongoing Additional Phase 3 Trial SAN DIEGO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of
Show more

Otonomy Company Life and Culture

Report incorrect company information

Otonomy Frequently Asked Questions

  • When was Otonomy founded?

    Otonomy was founded in 2008.

  • Who are Otonomy key executives?

    Otonomy's key executives are Paul E. Cayer.

  • How many employees does Otonomy have?

    Otonomy has 139 employees.

  • What is Otonomy revenue?

    Latest Otonomy annual revenue is $1.2 m.

  • What is Otonomy revenue per employee?

    Latest Otonomy revenue per employee is $8.9 k.

  • Who are Otonomy competitors?

    Competitors of Otonomy include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Otonomy headquarters?

    Otonomy headquarters is located at 6275 Nancy Ridge Dr, San Diego.

  • Where are Otonomy offices?

    Otonomy has an office in San Diego.

  • How many offices does Otonomy have?

    Otonomy has 1 office.